Literature DB >> 17573449

Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD.

Ioannis Vogiatzis1, Grigoris Stratakos, Davina C M Simoes, Gerasimos Terzis, Olga Georgiadou, Charis Roussos, Spyros Zakynthinos.   

Abstract

BACKGROUND: Skeletal muscle wasting commonly occurs in patients with chronic obstructive pulmonary disease (COPD) and has been associated with the presence of systemic inflammation. This study investigated whether rehabilitative exercise training decreases the levels of systemic or local muscle inflammation or reverses the abnormalities associated with muscle deconditioning.
METHODS: Fifteen patients with COPD (mean (SE) forced expiratory volume in 1 s 36 (4)% predicted) undertook high-intensity exercise training 3 days/week for 10 weeks. Before and after the training programme the concentration of tumour necrosis factor alpha (TNFalpha), interleukin-6 (IL-6) and C-reactive protein (CRP) in plasma was determined by ELISA, and vastus lateralis mRNA expression of TNFalpha, IL-6, total insulin-like growth factor-I (IGF-I) and its isoform mechanogrowth factor (MGF) and myogenic differentiation factor D (MyoD) were assessed by real-time PCR. Protein levels of TNFalpha, IGF-I and MyoD were measured by Western blotting.
RESULTS: Rehabilitation improved peak exercise work rate by 10 (2%) (p = 0.004) and mean fibre cross-sectional area from 4061 (254) microm(2) to 4581 (241) microm(2) (p = 0.001). Plasma inflammatory mediators and vastus lateralis expression of TNFalpha and IL-6 were not significantly modified by training. In contrast, there was a significant increase in mRNA expression of IGF-I (by 67 (22)%; p = 0.044), MGF (by 67 (15)%; p = 0.002) and MyoD (by 116 (30)%; p = 0.001). The increase observed at the mRNA level was also seen at the protein level for IGF-I (by 72 (36)%; p = 0.046) and MyoD (by 67 (21)%; p = 0.012).
CONCLUSIONS: Pulmonary rehabilitation can induce peripheral muscle adaptations and modifications in factors regulating skeletal muscle hypertrophy and regeneration without decreasing the levels of systemic or local muscle inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17573449      PMCID: PMC2117139          DOI: 10.1136/thx.2006.069310

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  39 in total

Review 1.  Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms.

Authors:  R Debigaré; C H Côté; F Maltais
Journal:  Am J Respir Crit Care Med       Date:  2001-11-01       Impact factor: 21.405

Review 2.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

Review 3.  Skeletal muscle dysfunction in chronic obstructive pulmonary disease and chronic heart failure: underlying mechanisms and therapy perspectives.

Authors:  H R Gosker; E F Wouters; G J van der Vusse; A M Schols
Journal:  Am J Clin Nutr       Date:  2000-05       Impact factor: 7.045

4.  Reduced muscle redox capacity after endurance training in patients with chronic obstructive pulmonary disease.

Authors:  R A Rabinovich; E Ardite; T Troosters; N Carbó; J Alonso; J M Gonzalez de Suso; J Vilaró; J A Barberà; M F Polo; J M Argilés; J C Fernandez-Checa; J Roca
Journal:  Am J Respir Crit Care Med       Date:  2001-10-01       Impact factor: 21.405

5.  Interval training as an alternative modality to continuous exercise in patients with COPD.

Authors:  I Vogiatzis; S Nanas; C Roussos
Journal:  Eur Respir J       Date:  2002-07       Impact factor: 16.671

6.  Dynamic hyperinflation and tolerance to interval exercise in patients with advanced COPD.

Authors:  I Vogiatzis; S Nanas; E Kastanakis; O Georgiadou; O Papazahou; Ch Roussos
Journal:  Eur Respir J       Date:  2004-09       Impact factor: 16.671

7.  Catabolic/anabolic balance and muscle wasting in patients with COPD.

Authors:  Richard Debigaré; Karine Marquis; Claude H Côté; Roland R Tremblay; Annie Michaud; Pierre LeBlanc; François Maltais
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

8.  Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients.

Authors:  R A Rabinovich; M Figueras; E Ardite; N Carbó; T Troosters; X Filella; J A Barberà; J C Fernandez-Checa; J M Argilés; J Roca
Journal:  Eur Respir J       Date:  2003-05       Impact factor: 16.671

9.  Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts.

Authors:  Suzanne R Broussard; Robert H McCusker; Jan E Novakofski; Klemen Strle; Wen Hong Shen; Rodney W Johnson; Gregory G Freund; Robert Dantzer; Keith W Kelley
Journal:  Endocrinology       Date:  2003-07       Impact factor: 4.736

10.  Diet but not aerobic exercise training reduces skeletal muscle TNF-alpha in overweight humans.

Authors:  K E Ferrier; P Nestel; A Taylor; B G Drew; B A Kingwell
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

View more
  31 in total

1.  Preview of highlighted presentations from the European Respiratory Society' clinical assembly.

Authors:  Nicolas Kahn; Lowie E G W Vanfleteren; Georgios Kaltsakas; Vasileios Andrianopoulos; Daniela Gompelmann; Corina de Jong; Felix J F Herth
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.

Authors:  Joaquim Gea; Carme Casadevall; Sergi Pascual; Mauricio Orozco-Levi; Esther Barreiro
Journal:  J Thorac Dis       Date:  2016-11       Impact factor: 2.895

Review 3.  Can muscle protein metabolism be specifically targeted by exercise training in COPD?

Authors:  Davina C M Simoes; Ioannis Vogiatzis
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 4.  Can muscle protein metabolism be specifically targeted by nutritional support and exercise training in chronic obstructive pulmonary disease?

Authors:  Ramzi Lakhdar; Roberto A Rabinovich
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

Review 5.  An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.

Authors:  François Maltais; Marc Decramer; Richard Casaburi; Esther Barreiro; Yan Burelle; Richard Debigaré; P N Richard Dekhuijzen; Frits Franssen; Ghislaine Gayan-Ramirez; Joaquim Gea; Harry R Gosker; Rik Gosselink; Maurice Hayot; Sabah N A Hussain; Wim Janssens; Micheal I Polkey; Josep Roca; Didier Saey; Annemie M W J Schols; Martijn A Spruit; Michael Steiner; Tanja Taivassalo; Thierry Troosters; Ioannis Vogiatzis; Peter D Wagner
Journal:  Am J Respir Crit Care Med       Date:  2014-05-01       Impact factor: 21.405

6.  Investigating activity in hospitalized patients with chronic obstructive pulmonary disease: a pilot study.

Authors:  Chris Winkelman
Journal:  Heart Lung       Date:  2010-04-08       Impact factor: 2.210

7.  A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3.

Authors:  Robert C Kaplan; Ann-Kristin Petersen; Ming-Huei Chen; Alexander Teumer; Nicole L Glazer; Angela Döring; Carolyn S P Lam; Nele Friedrich; Anne Newman; Martina Müller; Qiong Yang; Georg Homuth; Anne Cappola; Norman Klopp; Holly Smith; Florian Ernst; Bruce M Psaty; H-Erich Wichmann; Douglas B Sawyer; Reiner Biffar; Jerome I Rotter; Christian Gieger; Lisa S Sullivan; Henry Völzke; Kenneth Rice; Ariadni Spyroglou; Heyo K Kroemer; Y-D Ida Chen; Jenny Manolopoulou; Matthias Nauck; Howard D Strickler; Mark O Goodarzi; Martin Reincke; Michael N Pollak; Martin Bidlingmaier; Ramachandran S Vasan; Henri Wallaschofski
Journal:  Hum Mol Genet       Date:  2011-01-07       Impact factor: 6.150

8.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

Review 9.  Structural and functional changes of peripheral muscles in chronic obstructive pulmonary disease patients.

Authors:  Roberto A Rabinovich; Jordi Vilaró
Journal:  Curr Opin Pulm Med       Date:  2010-03       Impact factor: 3.155

10.  Calprotectin levels in patients with rheumatoid arthritis to assess and association with exercise treatment.

Authors:  Ayse Acar; Savas Guzel; Banu Sarifakioglu; Eda Celik Guzel; Aliye Yildirim Guzelant; Ceyda Karadag; Lebriz Kiziler
Journal:  Clin Rheumatol       Date:  2016-04-19       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.